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than men (75.5% vs 57.7%) and through randomisation got
their preference more often (48.7% vs. 26.7%, p 0.04). The
effects of patient preference on outcome was similar in men
and women, furthermore the overall results of this study were
independent of gender. Patients who had previously received an
IS were more likely to express a preference (83.1% vs. 60.4%,
p=0.003), but were less likely to receive it (32.7% vs. 50.9%,
p=0.002). Adjusting for previous intra-articular injections did not
significantly affect the overall results.
Conclusions: In this study, which demonstrated significant im-
provements for TI compared to IS, patient preference was also
a strong independent predictor of outcome. Those who did not
express a treatment preference obtained the best outcome and
those did not receive their preference did not benefit from the
treatments given. Previous studies suggesting that patient pref-
erence influences outcome have been conducted on treatments
with long term therapies and as such differences have been
attributed to adherence with treatment. This study of a single
baseline intervention suggests that compliance is not the only
reason and hence these findings have major implications for
clinical practice and for the design of future RCT’s.
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Purpose: Retention on treatment reflects the interrelated issues
of efficacy, safety and tolerability in OA patients. Objective: To
show that lumiracoxib 100 mg od and 100 mg bid are non-inferior
to celecoxib 200 mg od with respect to the retention rate at week
52 in patients with OA.
P302 – Table 1
Population treatment group N Retention rate Contrasts Estimated 97.5% CI Outcome
n (%) difference of difference
ITT
LUM 100mg od 755 354 (46.9) LUM 100mg od - CEL 200mg od 0.02 -0.04, 0.07 Non-inferiority shown
LUM 100mg bid 1519 722 (47.5) LUM 100mg bid - CEL 200mg od 0.02 -0.03, 0.07 Non-inferiority shown
CEL 200mg od 758 343 (45.3)
LUM = lumiracoxib; CEL = celecoxib.
Methods: In this 52 week, randomized, double-blind trial, 3036
patients with OA of the hip, knee, hand or spine were ran-
domized to lumiracoxib 100 mg od, lumiracoxib 100 mg bid (2x
recommended dose for OA) and celecoxib 200 mg od in a 1:2:1
ratio.
The primary efficacy variable was the retention rate at 52 weeks.
Non-inferiority was tested by comparing pairwise differences in
retention rates using a multiple testing procedure to adjust for
multiplicity and a confidence interval approach with a pre-defined
non-inferiority margin of -0.1. Secondary variables included effi-
cacy using patient’s assessment of OA pain intensity in the target
joint, patient’s and physician’s global assessment of disease ac-
tivity (defined as improvement by at least one grade in the Likert
scale), usage of rescue medication and safety and tolerability.
Results: Patient disposition was similar across the treatment
groups. Approximately 45% of patients in each group remained
on treatment until study end. An amendment to the protocol
following the announcement of possible increased CV risk with
celecoxib excluded patients with CCV history and elevated CV
risk (13%) and led to withdrawal of consent in 4% of the patients.
Other major reasons for discontinuations were adverse events
(12%), unsatisfactory therapeutic effect (11%) and withdrawal of
consent (7%).
The results of the retention to treatment analysis are shown in
Table 1.
Comparisons using an integrated measure of the overall level
of OA pain intensity and patient’s and physician’s global as-
sessments of disease activity showed no statistical significant
differences between treatment groups.
Improvement rates at study end for OA pain intensity (51 - 54%),
patient’s and physican’s global assessment and use of rescue
medication were comparable between the treatment goups.
The safety and tolerability of both lumiracoxib doses and cele-
coxib were generally similar, with comparable overall incidences
of AEs and SAEs. APTC events (stroke, MI, CV death) occurred
in similar rates (0.7-0.8%). ALT/AST elevations > 3 x ULN oc-
curred at a higher frequency in patients treated with lumiracoxib
100 mg bid (2x recommended dose) than with lumiracoxib 100
mg od or celecoxib 200 mg od.
Conclusions: Retention on treatment at 1 year of lumiracoxib
100mg od was non-inferior to celecoxib 200 mg od and all
secondary efficacy parameters were comparable between these
treatment groups. Lumiracoxib 100 mg od was shown to be as
effective and safe as celecoxib 200 mg od.
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Purpose: This trial is a prospective assessment of the effi-
cacy and tolerability of intra-articular sodium hyaluronate (SH;
S166 Poster Presentations
Ostenil mini) and triamcinolone (TA; Volon A10) for treatment
of osteoarthritis (OA) of the carpometacarpal (CMC) joint of the
thumb in a 26-week, controlled, randomized, masked-observer
study.
Methods: Patients were treated with three intra-articular injec-
tions of either SH (n=28) or TA (n=28). Primary assessments
were pain according to VAS and extensive clinical and func-
tional parameters such as swelling, grip power and range of
motion. The population was analysed using one- and two-sided
Mann-Whitney (MW) estimators.
Results: Maximum pain relief occurred at 2-3 weeks for TA and
at week 26 for SH after the first intra-articular injection. At weeks
2-3 TA was significantly better than SH (MW: 0.3319 and 0.3063;
p=0.9827 and 0.9929). At week 26 a slight superiority of SH could
be observed (MW: 0.53; p=0.3624) and non-inferiority could be
proven. After 26 weeks lateral pinch power was significantly
better in the SH-group (MW: 0.6331; p=0.0226). In all, 88.0% of
patients treated with SH and 79.2% of the TA-group described
pain improvement after 26 weeks. No adverse events with causal
connection to the investigational products occurred.
Conclusions: We conclude that a single course of three SH in-
jections is effective in relieving pain and improving joint function in
patients with OA of the CMC joint of the thumb. Although in com-
parison with triamcinolone its effects are achieved more slowly,
the results indicate a superior long-lasting effect of hyaluronan at
6 months after end of treatment period.
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Purpose: The present study determines whether the combina-
tion of Avocado Soy Unsaponifiables (ASU), glucosamine (Glu),
and chondroitin sulfate (CS) was more effective in suppressing
pro-inflammatory gene expression than ASU alone, or Glu and
CS together.
Methods: Human monocyte/macrophage surrogate THP-1 cells
(5 x 105 cells) were incubated for 24 hrs at 37°C and 5% CO2
with: (i) control media alone, (ii) ASU (8.3 μg/ml; NMX1000TM-
ASU), (iii) Glu (15 mM; FCHG49®) and CS (20 μg/ml; TRH122®),
or with (iv) a combination of ASU (8.3 μg/ml), Glu (15mM), and
CS (20 μg/ml). All test materials were supplied by Nutramax
Laboratories, Inc., Edgewood, MD. The cells were then activated
with 20 ng/ml LPS for 1 hour. Total RNA was extracted and
subjected to RT-PCR analysis using primers specific to TNF-α,
IL-1β, iNOS, p38, and S14 as the housekeeping gene.
Results: Pre-treatment with the combination of ASU, Glu, and
CS profoundly suppressed the expression of TNF-α, IL-1β, and
iNOS by 50-80% in activated THP-1 cells. The combination
treatment reduced TNF-α and IL-1β expression to levels similar
to baseline non-activated controls and reduced iNOS expression
to levels lower than baseline non-activated levels. The inhibitory
effect of the combined preparation on TNF-α, IL-1β, and iNOS
expression is more profound than ASU alone, or Glu and CS
together. The inhibition of cytokine and iNOS expression is
associated with a profound suppression of p38 expression.
Conclusions: In the present study, we demonstrate that the
combination of ASU, Glu, and CS was more effective in sup-
pressing pro-inflammatory gene expression than ASU alone, or
Glu and CS together. The combined preparation suppressed
TNF-α, IL-1β, and iNOS expression by downregulating p38, a
key signal transduction molecule involved in inflammation. Our
present findings suggest the utility of the combination product
to alleviate pain and inflammation in OA patients who may not
clinically respond to Glu and CS alone.
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Purpose: Thermotherapy is widely used to conservatively treat
joint diseases such as osteoarthritis (OA). While heat stimulation
of joints increases pain threshold to alleviate pain, its effects
on the articular cartilage have not been clarified. In the present
study, heat stimulation was applied to rabbit knee joints to in-
vestigate the changes in expressions of heat shock protein 70
(HSP70) and cartilage matrix genes in the articular cartilage in
vivo.
Methods: Heat stimulation (0-80 W) was applied to the knee
joints of Japanese white rabbits for 20 min using a microwave
applicator (2.45-GHz). After 8-72 hrs, the articular cartilage was
removed from the knee joints and proteins and total RNA were
extracted. As controls, the knee joints without heat stimulation
were analyzed. Expression of HSP70 was confirmed by real-
time PCR and Western blotting. Expression of proteoglycan core
protein and type II collagen were quantified using real-time PCR
to assess cartilage matrix metabolism.
Results: Compared to controls, expression of HSP70 mRNA was
higher with not less than 40 W of heat stimulation in an intensity-
dependent manner. Expressions of proteoglycan core protein
and type II collagen mRNA were higher with not less than 20 W
of heat stimulation and peaked with 40 W. When quercetin was
used to block the increases in HSP70 expression, the expression
of proteoglycan core protein mRNA did not increase.
Conclusions: External heat stimulation increased expression of
HSP70 in the articular cartilage. This suggested that external
heat stimulation reached the articular cartilage. Heat stimulation
also increased expression of proteoglycan core protein and type
II collagen mRNA in the articular cartilage, indicating increased
cartilage metabolism. HSP70 might thus be involved in the in-
creased expression of proteoglycan core protein. With some
improvements, heat stimulation might be actively used to protect
the cartilage in OA.
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Purpose: A syncretic drug comprises two compounds that are
designed to act synergistically through multiple pathways to pro-
vide a novel therapeutic effect, which neither component can
achieve alone. The syncretic drug candidate CRx-102 comprises
dipyramidole and low dose prednisolone and is in clinical de-
